News
23 January 2012
23 January 2012
BIOMARKERS AND IMAGING (International Conference on Sarcopenia Research). Report on the Journal of Nutrition, Health & Aging © (Volume 15, Number 10, 2011).
5 December 2011
5 December 2011
Neurotune AG is Coordinator of an Eurostars funded Project entitled “Early Diagnosis and Monitoring of Renal Diseases” (Acronym: KIDNEY).
The scope of the project is the validation of a new and most effective diagnostic biomarker (RCAF) for the early monitoring of chronic kidney disease with a possible application in the prognosis of kidney transplant and in acute kidney injury.
16 November 2011
16 November 2011
Neurotune AG has presented three scientific communications at the International Neuroscience Meeting held in Washington DC on Nov 12 -16, 2011. The data presented were reporting results of original experiments performed in Neurotune’s laboratories in Schlieren and others carried out in conjunction with researchers of University of Florence.
14 November 2011
14 November 2011
Schlieren (Zurich), Switzerland, 14 November 2011. The FDA has granted Neurotune AG an IND for dimiracetam, the company’s lead compound for treatment of neuropathic pain conditions. Neurotune is planning a pivotal study to demonstrate efficacy of dimiracetam in alleviating neuropathic pain in AIDS patients affected with a treatment related symmetrical painful peripheral neuropathy.
26 September 2011
26. September 2011
Erste Publikation des Amts für Wirtschaft und Arbeit - Interview mit Bruno Oesch
Bruno Oesch, Mitgründer der Prionics AG und Verwaltungsratspräsident der Neurotune AG, über die Wahrnehmung unseres Standortes und Synergien in der Life-Science-Branche.
12 April 2011
12 April 2011
Neurotune Strengthens Management
Neurotune AG, a Swiss biopharmaceutical company, today announced personnel changes in its board of directors as well as management.
More
23 February 2011
23 February 2011
Neurotune receives EU funding for sarcopenia project
Neurotune AG today announced it is leading a consortium of research teams in the DISARCO project, a two-year project focused on developing an immunoassay for the diagnosis of sarcopenia. The consortium has received €720,000 from the European Eurostars Programme to fund the research.
More
12 January 2011
12 January 2011
Der BIO-TECHNOPARK® Schlieren-Zürich ist zusammen mit Neurotune, ETH Zürich, Universität Zürich und der Standortförderung des Kantons Zürich Partner im EU-Projekt HealthTIES.
More
16 December 2010
16 December 2010
Neurotune wins the third place in the 2010 Eurecan European Venture Contest (EEVC) finals in the category healthcare companies. The finalists were selected by an international jury out of 987 applications from 24 countries.
More
21 October 2010
21 October 2010
Neurotune announces positive top-line Phase IIa results for dimiracetam to treat neuropathic pain in HIV patients
Neurotune AG, a Swiss biopharmaceutical company, today announced positive top-line results from its phase IIa, safety and tolerability, study of dimiracetam (NT-11624), its lead compound for treatment-induced neuropathic pain in HIV patients receiving anti-retroviral medication.
More
27 April 2010
27 April 2010
Painless future: new members for Board of Directors, funding and clinical results outlook
The shareholders of Neurotune AG have elected Dr. Anders Härfstrand and Heinrich Rotach as new members of the board of directors at their annual general assembly on April 21, 2010.
More
17 August 2009
17 August 2009
Neurotune announces regulatory approval for Phase II Clinical Trial to treat neuropathic pain in HIV patients
Neurotune AG has received MCC ’s (the South African National Regulatory Agency) approval for a Phase II clinical study of Neurotune’s lead compound NT-11624 for neuropathic pain caused by treatment with anti-retroviral medication.
More
26 January 2009
26 January 2009
Change in the Management of Neurotune AG
Neurotune AG announces a change in the management. Starting March 1st 2009, Dr. Bruno Oesch will take over the position of Chief Executive Officer.
More
15 January 2009
15 January 2009
Neurotune successfully completes Phase I Trials with its Lead Compund NT-11624
Neurotune AG, a Swiss biopharmaceutical company, which has recently acquired two programs in neuropathic pain, announces the successful completion of Phase I for its lead compound NT-11624 developed for treatment of neuropathic and osteoarthritic pain. NT-11624, dimiracetam, is a selective small molecular NMDA-receptor antagonist, which acts on a new site of the receptor.
More
18 September 2008
18 September 2008
Neurotune expands its portfolio by acquiring neuropathic pain projects
Neurotune AG announces that the shareholders meeting, held on August 29th 2008, approved of the expansion of its portfolio with two programs in neuropathic pain. The company has reached an agreement with the Italy-based company Brane Discovery Srl. to acquire rights for two programs in neuropathic pain in a combined cash and share transaction.
More
29 July 2008
29 July 2008
Neurotune completes next funding round
Neurotune AG announces the closing of the fourth funding round. Another single-digit million Swiss francs will accrue to the company. The company will use the increase in capital to advance the development of its therapeutical approach to treat sarcopenia and along with this the diagnostical methods. Part of the capital will be used to extend a developmental pipeline.
More
7 November 2007
7 November 2007
Neurotune moves to new laboratories and starts the preclinical development of initial candidate substances for the treatment of sarcopenia
Neurotune AG has moved to new laboratory and office facilities at the Biotech Centre in Zurich on 1st November 2007.
More
1 August 2007
1 August 2007
Neurotune expands its management by taking on an expert for preclinical development and appointing a new CFO
Neurotune AG has taken on Dr. Jan Willem Vrijbloed for the expansion of its preclinical development division, and has appointed Michael Kregar as the new Chief Financial Officer (CFO).
More
19 June 2007
19 June 2007
Neurotune AG is honoured on the occasion of the award ceremony „ZKB Pioneer Award TECHNOPARK® 2007“
Neurotune AG was awarded a prize for its activity in the area of developing drugs to treat age-related muscle atrophy – Sarcopenia – and other disorders of the human nervous system on Tuesday evening.
More
21-22 May 2007
21-22 May 2007
Neurotune to present during the Next Wave Session at the BioEquity 2007, in Glasgow, Scotland.
For more information, please see http://www.ebdgroup.com/bioequity/
13 April 2007
13 April 2007
Neurotune announces closing of 3rd Seed Financing Round
With the conclusion of its third Seed Round Financing, Neurotune adds another CHF 3.3 Mio to its funds.
More
2 April 2007
2 April 2007
Neurotune AG and NiKem Research Srl enter into a Research Service Agreement
Neurotune and NiKem Research announced that the two companies have signed a 12 months Research Service Agreement on 1 February, 2007.
More
6-8 November 2006
6-8 November 2006
Neurotune to present at the BioEurope 2006, November 6-8, Düsseldorf, Germany.
For more information, please see www.ebdgroup.com/bioeurope/
13 October 2006
13 October 2006
Neurotune to present at the 2nd Swiss-Scandinavian Bio-Business Seminar, October 13, 2006, Zürich, Switzerland.
For more information, please see www.greaterzuricharea.ch
19-21 September 2006
19-21 September 2006
Meet us at the Biobusiness Network 2006 Partnering Conference at the Hotel President Wilson, Geneva, Switzerland.
For more information, please see www.biobusiness-partnering.com
26 June 2006
26 June 2006
Neurotune announces second closing of Seed Financing Round
With the conclusion of its Second Seed Round Financing Neurotune adds another CHF 2.5 Mio to its funds.
Press Release N°: 2006/03
[Download PDF]
22-23 May 2006
22-23 May 2006
Neurotune to present at the BioEquity Europe 2006 in Frankfurt/Main, Germany during the Next Wave presentation session on Monday, May 22.
For more information, please see www.biocentury.com or www.ebdgroup.com
17 May 2006
17 May 2006
Neurotune successfully concludes CHF 4.9 Mio. Private Equity Financing Round
Second Seed Round Financing through Private Equity and Loan from Existing and New Investors.
Press Release N°: 2006/02
[Download PDF]
6 February 2006
6 February 2006
Neurotune appoints new CEO Dr. Andreas J. Schulze is new CEO of Neurotune AG.
Press Release N°: 2006/01
[Download PDF]
5 December 2011
Neurotune AG is coordinator of an Eurostars funded project entitled "Early Diagnosis and Monitoring of Renal Diseases" (Acronym: KIDNEY).
16 November 2011
Neurotune presents at the International Neuroscience Meeting in Washington.